Sort
10,766 grants matching “checkpoint inhibitor”
Targeting STAT3 to enhance anti-tumor immunity
$636,402Daniel E Johnson · University Of California, San Francisco · R01 · FY2021 · DE
Image-guided cancer therapy using heat activatable CAR T cells
$636,385Stanislav Y Emelianov · Georgia Institute Of Technology · R01 · FY2025 · EB
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
$636,267Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2022 · CA
Defining mechanisms of how immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer
$636,222Marlies Meisel · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer
$636,160Natalie Vokes · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$635,965Dung T Le · Johns Hopkins University · P01 · FY2024 · CA
Melanocyte PDL1 control of UVB-induced IFN-I
$635,946Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2024 · CA
Melanocyte PDL1 control of UVB-induced IFN-I
$635,946Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2025 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$635,854Michelle S Bradbury · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
$635,757Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2023 · CA
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
$635,712Powel Brown · University Of Tx Md Anderson Can Ctr · N01 · FY2021 · CA
Precision targeting of T cell cytotoxicity with PET
$635,683Michael John Evans · University Of California, San Francisco · R01 · FY2023 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.
$635,587Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2018 · CA
Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer
$635,516Stephanie Subasic Markovina · Washington University · R37 · FY2025 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$635,258Edward B Garon · University Of California Los Angeles · R01 · FY2018 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$635,207Edward B Garon · University Of California Los Angeles · R01 · FY2021 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$635,187Edward B Garon · University Of California Los Angeles · R01 · FY2020 · CA
Microtubule Regulation
$635,178Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2011 · GM
Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in Glioblastoma
$635,095Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R35 · FY2024 · NS
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer
$634,953Keith L Knutson · Mayo Clinic Jacksonville · R01 · FY2023 · CA
Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer
$634,894Stephanie Subasic Markovina · Washington University · R37 · FY2024 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$634,715Elad Ziv · University Of California, San Francisco · R01 · FY2019 · CA
Data Processing, Analysis and Modeling Unit
$634,712Jeremy Goecks · Oregon Health & Science University · U2C · FY2019 · CA
PI3K Pathway Mutations in Head and Neck Cancer
$634,703Jennifer R Grandis · University Of California, San Francisco · R01 · FY2022 · DE
Tailoring CAR T cell therapy for Hodgkin Lymphoma
$634,693Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA